These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 23981744)

  • 1. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
    J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
    Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
    Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
    Yu KH; Yu CY; Fang YF
    Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
    Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
    Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
    Jutkowitz E; Dubreuil M; Lu N; Kuntz KM; Choi HK
    Semin Arthritis Rheum; 2017 Apr; 46(5):594-600. PubMed ID: 27916277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
    Dainichi T; Uchi H; Moroi Y; Furue M
    Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
    [No Abstract]   [Full Text] [Related]  

  • 11. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.
    Cheng L; Xiong Y; Qin CZ; Zhang W; Chen XP; Li J; Zhou HH
    Br J Dermatol; 2015 Aug; 173(2):555-8. PubMed ID: 26104483
    [No Abstract]   [Full Text] [Related]  

  • 12. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
    Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
    Zineh I; Mummaneni P; Lyndly J; Amur S; La Grenade LA; Chang SH; Rogers H; Pacanowski MA
    Pharmacogenomics; 2011 Dec; 12(12):1741-9. PubMed ID: 22118056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
    Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
    Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
    Saokaew S; Tassaneeyakul W; Maenthaisong R; Chaiyakunapruk N
    PLoS One; 2014; 9(4):e94294. PubMed ID: 24732692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.
    Caldarola G; Sollena P; Peris K; De Simone C
    J Dermatol; 2015 Jul; 42(7):753-4. PubMed ID: 25899558
    [No Abstract]   [Full Text] [Related]  

  • 19. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
    Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
    Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
    Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.